InvestorsHub Logo
Followers 412
Posts 29526
Boards Moderated 3
Alias Born 02/25/2006

Re: bUrRpPPP! post# 233442

Friday, 12/13/2019 4:30:09 PM

Friday, December 13, 2019 4:30:09 PM

Post# of 425641
FDA approved Vascepa as an adjunctive (secondary) therapy to reduce the risk of CV events among adults with elevated TG of 150 mg/dL or higher. Patients must also have either established CV disease or diabetes and two or more additional risk factors for CV disease.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News